Inventors with similar research interests:
Location History:
- Greefield Park, CA (2003)
- Quebec, CA (1995 - 2006)
- Greenfield Park, CA (1990 - 2024)
- Montreal, CA (2019 - 2024)
Company Filing History:
48 out of 3,684 
8 out of 183 
2 out of 42 
Years Active: 1990-2024
Areas of Expertise:
Title: Edward H. Ruediger: A Pioneer in Pharmaceutical Innovations
Introduction
Edward H. Ruediger, based in Greenfield Park, CA, is a prominent inventor in the field of pharmaceuticals, holding a remarkable 51 patents. His work focuses on developing innovative compounds that target critical pathways in treating various medical conditions, particularly those related to platelet aggregation and receptor activity.
Latest Patents
Among Ruediger’s latest patents are significant inventions aimed at enhancing therapeutic options for patients. One notable patent details "Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation." This invention provides thiazole compounds of a specific formula that serve as inhibitors of platelet aggregation, offering potential treatments for thromboembolic disorders.
Another important patent outlines "Biarylmethyl heterocycles." This invention includes compounds that act as biased agonists, or β-Arrestin agonists of the angiotensin II receptor, indicating their potential use as medicaments. Both inventions showcase Ruediger's commitment to advancing pharmaceutical science and improving patient care.
Career Highlights
Throughout his career, Edward H. Ruediger has contributed to significant advancements in drug development. His experience includes working with Bristol-Myers Squibb Company, a leading global biopharmaceutical company. Additionally, his association with the Université De Montréal highlights his involvement in academic research and collaboration with academic institutions, strengthening the bridge between research and practical applications.
Collaborations
Ruediger has collaborated with notable colleagues such as Daniel H. Deon and Carol Bachand, contributing to a dynamic network of innovators in the pharmaceutical field. These collaborations have allowed for the exchange of ideas and the development of groundbreaking solutions within the industry.
Conclusion
Edward H. Ruediger exemplifies the spirit of innovation in pharmaceuticals, with a substantial portfolio of patents and impactful collaborations. His work continues to pave the way for new treatments and therapies, highlighting the essential role of inventors in advancing medical science and improving health outcomes.